Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Transgender Care
Are there specific considerations to take into account when managing a patient with RA on conventional DMARDs who is receiving gender affirming hormone therapy?
Related Questions
What is your approach to the evaluation of a patient with persistent costochondritis?
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
How do you approach contraception counseling with transgender patients taking gender affirming hormone therapy prior to starting teratogenic medications?
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
How do you manage a patient with severe RA or SLE that worsens after stopping immunosuppressants due to having chronic foot ulceration?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
Do you combine methotrexate and leflunomide for the treatment of RA?
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
Would you have a patient temporarily discontinue methotrexate while receiving a FAST or FAST FORWARD regimen for breast irradiation?
How do you approach managing nausea and GI side effects when initiating methotrexate?
